SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia | Zendy

Thomas M. File | Zendy; Barbara Rewerska | Zendy; Violeta Vučinić-Mihailović | Zendy; Joven Gog | Zendy; Anita Das | Zendy; Kara Keedy | Zendy; David Taylor | Zendy; Amanda Sheets | Zendy; Prabhavathi Fernandes | Zendy; David Oldach | Zendy; Brian Jamieson | Zendy

Open Access

SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia

Author(s) -

Thomas M. File,

Barbara Rewerska,

Violeta Vučinić-Mihailović,

Joven Gog,

Anita Das,

Kara Keedy,

David Taylor,

Amanda Sheets,

Prabhavathi Fernandes,

David Oldach,

Brian Jamieson

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw490

Subject(s) - medicine , moxifloxacin , adverse effect , population , dosing , randomized controlled trial , clinical endpoint , pneumonia , community acquired pneumonia , bacterial pneumonia , confidence interval , surgery , antibiotics , environmental health , microbiology and biotechnology , biology

Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research